News / Taiwan / cnyes
Huaan August Revenue Jumps 153%, Outperforming Biotech Sector
Health Technology · Biotechnology · cnyes · 2026-09-08
6657
Biotech firm Huaan (6657) reported a 153.31% year-over-year revenue increase for August 2026, supported by recent institutional buying and strong relative stock performance.
What Happened
Revenue Momentum: Huaan (6657) announced August 2026 revenue of NT$800,000, marking a 153.31% year-over-year increase and a 30.78% month-over-month gain. Despite the small scale of revenue, the growth rates indicate a significant upward trend.
Cumulative Performance: The company's cumulative revenue for the first eight months of 2026 reached NT$4.66 million, representing a year-to-date growth of 14.02%. This reflects steady progress in the company's operational scaling.
Institutional Activity: Over the past five trading days, institutional investors have net bought 115 shares, with foreign investors accounting for 114 of those shares. This influx of capital suggests growing confidence from institutional players.
Market Performance: Shares of Huaan closed at NT$30.45, posting a 0.33% gain over the last five days. This performance outperformed the biotech and medical sector index, which declined by 4.34% during the same period.